A5100916743- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Retinoids in leukemia and cellular processes
- Chronic Myeloid Leukemia Treatments
- Cancer-related gene regulation
- Chemical Analysis and Environmental Impact
- Social and Behavioral Studies
- Genetic Syndromes and Imprinting
- Pancreatic function and diabetes
- Kruppel-like factors research
- Renal and related cancers
- Diabetes Treatment and Management
- T-cell and B-cell Immunology
- Hepatitis B Virus Studies
- Hepatitis Viruses Studies and Epidemiology
- Birth, Development, and Health
- Iron Metabolism and Disorders
- Epigenetics and DNA Methylation
- Metabolism, Diabetes, and Cancer
- Neurogenetic and Muscular Disorders Research
- Viral gastroenteritis research and epidemiology
- Acute Lymphoblastic Leukemia research
- Effects and risks of endocrine disrupting chemicals
Beijing Hospital
2011-2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2020-2023
National Institute for Viral Disease Control and Prevention
2007
Abstract Purpose: The purpose of this study was to investigate the remodeling multiple myeloma microenvironment after B-cell maturation antigen (BCMA)–targeted chimeric receptor T (CAR-T) cell therapy. Experimental Design: We performed single-cell RNA sequencing on paired bone marrow specimens (n = 14) from seven patients with before (i.e., baseline, “day −4”) and 28”) lymphodepleted BCMA CAR-T Results: Our analysis revealed heterogeneity in gene expression profiles among cells, even those...
Background: The aim of this study was to clarify the relationship among Rac1 expression and activation, oxidative stress β cell dysfunction in obesity. Methods: In vivo, serum levels glucose, insulin, markers were compared between ob/ob mice C57BL/6J controls. Then, these variables rechecked after administration specific inhibitor-NSC23766 mice. vitro, NIT-1 cells cultured a hyperglycemic and/or hyperlipidemic state with or without NSC23766, differences translocation, NADPH oxidase(Nox)...
THZ1, a CDK7 inhibitor, has potent antitumor effects in several cancers; however, its role Acute myeloid leukemia (AML) is unclear. We explored the and potential mechanisms of alone combination with azacitidine (AZA), AML cells xenograft models. THZ1 decreased cell viability, induced apoptosis dose time-dependent manner, G0/G1 cycle arrest, phosphorylated CDK1 CDK2 expression, inhibited RNA Pol II phosphorylation at multiple serine sites. The AZA exhibited synergistic antileukemic lines...
The safety of hypoglycemic drugs should be paid more attention to in elderly patients with type 2 diabetes mellitus due their concomitant diseases, physiological decline liver and kidney function cognitive decline. aim this study was evaluate the efficacy DPP-4 inhibitors mellitus.From January 2010 November 2018, 300 who were over 60 years old enrolled outpatient clinic Geriatric Medical Center. Their medication records follow-up medical used for retrospective analysis. duration treatment...
Some previous researches raised the possibility of a novel acute myeloid leukemia (AML) entity presenting cup-like cytomorphology with mutations both FLT3 and NPM1 or one them. However, clinical implications this subtype remain unknown. We describe 63-year-old patient belonging to distinct AML subtype, who presented similar features promyelocytic (APL) including nuclear morphology, negative for CD34 HLA-DR, abnormal coagulation. He had no response arsenic trioxide CAG regimen (cytarabine,...
To explore the clinical characteristics and prognostic value of monosomal karyotype (MK) patients in adult acute myeloid leukemia (AML).We retrospectively studied 45 MK⁺ newly-diagnosed AML our center from Oct 2000 to Dec 2012. Clinical characteristics, cytogenetic data features were analyzed cohort patients.MK was found (19.0%) 237 with available at diagnoses. Among these cases, there 28 male (62.2%) 17 female (37.8%). Median age diagnose 58(18-91) years old. The presence -5(31.1%)...
<p>Supplementary Figure S5. BCMA CAR-T Therapy Enhances the Proportion and Cytotoxic Activity of CD8+ Effector T Cells, Positively Correlating with Therapeutic Responsivity.</p>
<p>Supplementary Figure S4. Quality Control of the Public scRNA-seq Dataset and Clustering Cells within MM Microenvironment.</p>
<p>Supplementary Figure S4. Quality Control of the Public scRNA-seq Dataset and Clustering Cells within MM Microenvironment.</p>
<p>Supplementary Figure S3. Cytogenetic Abnormality-associated Gene Expression and Clonal Evolution in MM Cells.</p>
<p>Supplementary Figure S1. Quality Control of the scRNA-seq Data.</p>
<p>Supplementary Figure S1. Quality Control of the scRNA-seq Data.</p>
<div>AbstractPurpose:<p>The purpose of this study was to investigate the remodeling multiple myeloma microenvironment after B-cell maturation antigen (BCMA)–targeted chimeric receptor T (CAR-T) cell therapy.</p>Experimental Design:<p>We performed single-cell RNA sequencing on paired bone marrow specimens (<i>n</i> = 14) from seven patients with before (i.e., baseline, “day −4”) and 28”) lymphodepleted BCMA CAR-T therapy.</p>Results:<p>Our...
<p>Supplementary Figure S2. Clustering of the Cells within MM Microenvironment.</p>
<p>Supplementary Figure S2. Clustering of the Cells within MM Microenvironment.</p>
<p>Supplementary Figure S3. Cytogenetic Abnormality-associated Gene Expression and Clonal Evolution in MM Cells.</p>
<p>Supplementary Figure S5. BCMA CAR-T Therapy Enhances the Proportion and Cytotoxic Activity of CD8+ Effector T Cells, Positively Correlating with Therapeutic Responsivity.</p>
<p>Supplementary Figure S6. BCMA CAR-T Therapy Enhances the Proportion and Cytotoxic Activity of CD8+ Effector T Cells, Positively Correlating with Therapeutic Responsivity.</p>
<p>Supplementary Figure S7. BCMA CAR-T Therapy Attenuates BAFF/GALECTIN/MK Pathway-mediated Immunosuppression and Activates MIF Anti-MM Immunity.</p>
<p>Supplementary Figure S6. BCMA CAR-T Therapy Enhances the Proportion and Cytotoxic Activity of CD8+ Effector T Cells, Positively Correlating with Therapeutic Responsivity.</p>
<div>AbstractPurpose:<p>The purpose of this study was to investigate the remodeling multiple myeloma microenvironment after B-cell maturation antigen (BCMA)–targeted chimeric receptor T (CAR-T) cell therapy.</p>Experimental Design:<p>We performed single-cell RNA sequencing on paired bone marrow specimens (<i>n</i> = 14) from seven patients with before (i.e., baseline, “day −4”) and 28”) lymphodepleted BCMA CAR-T therapy.</p>Results:<p>Our...